OTCMKTS:INNV - Innovus Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.11 -0.01 (-6.78 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$0.1180
Today's Range$0.11 - $0.1195
52-Week Range$0.0780 - $0.21
Volume568,256 shs
Average Volume934,688 shs
Market Capitalization$23.29 million
P/E Ratio-2.75
Dividend YieldN/A
Beta3.94

About Innovus Pharmaceuticals (OTCMKTS:INNV)

Innovus Pharmaceuticals logoInnovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence. The company's pipeline products include FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; Xyralid, a lidocaine based cream for the relief of pain and symptoms caused by hemorrhoids; AllerVarx, a patented formulation produced in bilayer tablets; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive INNV News and Ratings via Email

Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:INNV
CUSIPN/A
Phone858-964-5123

Debt

Debt-to-Equity RatioN/A
Current Ratio1.06
Quick Ratio0.81

Price-To-Earnings

Trailing P/E Ratio-2.75
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.82 million
Price / Sales2.42
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book11.00

Profitability

EPS (Most Recent Fiscal Year)($0.04)
Net Income$-6,500,000.00
Net Margins-51.76%
Return on Equity-273.00%
Return on Assets-49.94%

Miscellaneous

Employees12
Outstanding Shares194,050,000

Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals (OTCMKTS:INNV) released its earnings results on Monday, April, 2nd. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $2.38 million for the quarter. Innovus Pharmaceuticals had a negative return on equity of 273.00% and a negative net margin of 51.76%. View Innovus Pharmaceuticals' Earnings History.

Who are some of Innovus Pharmaceuticals' key competitors?

Who are Innovus Pharmaceuticals' key executives?

Innovus Pharmaceuticals' management team includes the folowing people:
  • Dr. Bassam B. Damaj Ph.D., Chief Exec. Officer, Pres & Director (Age 50)
  • Mr. Rauly Gutierrez CPA, Principal Financial and Accounting Officer
  • Mr. Randy J. Berholtz Esq., J.D., MBA, Exec. VP - Corp. Devel. & Gen. Counsel (Age 57)
  • Mr. Robert C. Verfurth, VP of Sales & Marketing

Has Innovus Pharmaceuticals been receiving favorable news coverage?

Media headlines about INNV stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Innovus Pharmaceuticals earned a news sentiment score of 0.15 on Accern's scale. They also gave media coverage about the company an impact score of 46.62 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innovus Pharmaceuticals' stock price today?

One share of INNV stock can currently be purchased for approximately $0.11.

How big of a company is Innovus Pharmaceuticals?

Innovus Pharmaceuticals has a market capitalization of $23.29 million and generates $8.82 million in revenue each year. The company earns $-6,500,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Innovus Pharmaceuticals employs 12 workers across the globe.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]


MarketBeat Community Rating for Innovus Pharmaceuticals (INNV)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  129
MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe INNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Innovus Pharmaceuticals (OTCMKTS:INNV) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 5/22/2016 forward)

Earnings

Innovus Pharmaceuticals (OTCMKTS:INNV) Earnings History and Estimates Chart

Earnings by Quarter for Innovus Pharmaceuticals (OTCMKTS:INNV)

Innovus Pharmaceuticals (OTCMKTS:INNV) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.01 EPS

Innovus Pharmaceuticals (OTCMKTS INNV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/2/2018Q4 2017($0.01)$2.38 millionViewN/AView Earnings Details
11/14/2017Q3 2017($0.01)$2.22 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.01)$2.04 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.02)$2.18 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.02)$1.69 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.01)$1.88 millionViewN/AView Earnings Details
8/15/2016Q2 2016($0.05)$1.02 millionViewN/AView Earnings Details
5/16/2016Q1 2016($0.02)$0.23 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Innovus Pharmaceuticals (OTCMKTS:INNV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Innovus Pharmaceuticals (OTCMKTS INNV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.14%
Insider Trading History for Innovus Pharmaceuticals (OTCMKTS:INNV)

Innovus Pharmaceuticals (OTCMKTS INNV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/23/2017Henry Jemil EsberDirectorBuy100,000$0.09$9,000.00View SEC Filing  
11/22/2017Randy BerholtzEVPBuy16,880$0.10$1,688.00View SEC Filing  
6/12/2013Bassam DamajCEOBuy416,841$0.32$133,389.12View SEC Filing  
2/2/2013Bassam DamajCEOBuy250,406$0.48$120,194.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Innovus Pharmaceuticals (OTCMKTS INNV) News Headlines

Source:
DateHeadline
Innovus Pharma launches Vesele in CanadaInnovus Pharma launches Vesele in Canada
seekingalpha.com - May 17 at 10:31 AM
Innovus Pharma Announces the Launch of its Product Vesele® in CanadaInnovus Pharma Announces the Launch of its Product Vesele® in Canada
finance.yahoo.com - May 17 at 10:31 AM
Innovus Pharma (INNV) Reports Q1 Loss of $0.01Innovus Pharma (INNV) Reports Q1 Loss of $0.01
www.streetinsider.com - May 15 at 4:04 PM
Innovus Pharmaceuticals Reports Record Quarterly Revenue for the First Quarter 2018 of $4.5 million, Beating Previous Estimate and Net Loss Decrease of 28% Compared to the Same Quarterly Period in 2017Innovus Pharmaceuticals Reports Record Quarterly Revenue for the First Quarter 2018 of $4.5 million, Beating Previous Estimate and Net Loss Decrease of 28% Compared to the Same Quarterly Period in 2017
finance.yahoo.com - May 15 at 10:53 AM
Innovus Pharmaceuticals (INNV) Upgraded at ValuEngineInnovus Pharmaceuticals (INNV) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 10:34 PM
Innovus Pharma Announces U.S. Food and Drug Administration Clearance of its GlucoGorx™ Glucose Monitoring Device Test KitInnovus Pharma Announces U.S. Food and Drug Administration Clearance of its GlucoGorx™ Glucose Monitoring Device Test Kit
finance.yahoo.com - April 21 at 9:56 AM
Innovus Pharma Announces Its Direct Launch of Apeaz™, a Cream for Arthritis Pain Relief, in CanadaInnovus Pharma Announces Its Direct Launch of Apeaz™, a Cream for Arthritis Pain Relief, in Canada
finance.yahoo.com - April 21 at 9:56 AM
Critical Contrast: Innovus Pharmaceuticals (INNV) and Its CompetitorsCritical Contrast: Innovus Pharmaceuticals (INNV) and Its Competitors
www.americanbankingnews.com - April 17 at 1:19 PM
Innovus Pharmaceuticals (INNV) Raised to Hold at Zacks Investment ResearchInnovus Pharmaceuticals (INNV) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 16 at 12:19 AM
Innovus Pharmaceuticals (INNV) Rating Lowered to Sell at Zacks Investment ResearchInnovus Pharmaceuticals (INNV) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 14 at 7:21 AM
Innovus Pharma announces direct launch of Apeaz in CanadaInnovus Pharma announces direct launch of Apeaz in Canada
seekingalpha.com - April 13 at 10:42 AM
Innovus Pharmaceuticals Inc (INNV) Forecasted to Post FY2018 Earnings of ($0.01) Per ShareInnovus Pharmaceuticals Inc (INNV) Forecasted to Post FY2018 Earnings of ($0.01) Per Share
www.americanbankingnews.com - April 13 at 9:22 AM
Innovus Pharmaceuticals (INNV) Rating Increased to Hold at Zacks Investment ResearchInnovus Pharmaceuticals (INNV) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 9 at 4:05 PM
Innovus Pharmaceuticals (INNV) versus Its Rivals Head-To-Head ReviewInnovus Pharmaceuticals (INNV) versus Its Rivals Head-To-Head Review
www.americanbankingnews.com - April 6 at 9:02 AM
Innovus Pharmaceuticals slides 10% post Q4 resultsInnovus Pharmaceuticals slides 10% post Q4 results
seekingalpha.com - April 4 at 5:44 PM
Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 Million to $4.4 Million and Expects to Exit 2018 ProfitableInnovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 Million to $4.4 Million and Expects to Exit 2018 Profitable
finance.yahoo.com - April 3 at 10:33 AM
Zacks Investment Research Lowers Innovus Pharmaceuticals (INNV) to HoldZacks Investment Research Lowers Innovus Pharmaceuticals (INNV) to Hold
www.americanbankingnews.com - March 31 at 12:46 AM
Head-To-Head Analysis: Innovus Pharmaceuticals (INNV) & The CompetitionHead-To-Head Analysis: Innovus Pharmaceuticals (INNV) & The Competition
www.americanbankingnews.com - March 27 at 3:20 PM
Innovus Pharmaceuticals (INNV) Lifted to Sell at ValuEngineInnovus Pharmaceuticals (INNV) Lifted to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 4:48 PM
Innovus Pharmaceuticals to Release Annual 2017 Financial Results, Preliminary First Quarter 2018 Revenues and Provide Corporate Update on Monday, April 2, 2018Innovus Pharmaceuticals to Release Annual 2017 Financial Results, Preliminary First Quarter 2018 Revenues and Provide Corporate Update on Monday, April 2, 2018
finance.yahoo.com - March 24 at 10:27 AM
Innovus Pharma’s AllerVarx™ Receives Commercial Approval by Health Canada for the Reduction in Symptoms of Seasonal Allergic RhinitisInnovus Pharma’s AllerVarx™ Receives Commercial Approval by Health Canada for the Reduction in Symptoms of Seasonal Allergic Rhinitis
finance.yahoo.com - February 28 at 10:11 AM
Innovus Pharma Launches its New Brand, Logo and its Latest E-Commerce-Enhanced Content WebsiteInnovus Pharma Launches its New Brand, Logo and its Latest E-Commerce-Enhanced Content Website
finance.yahoo.com - February 27 at 10:21 AM
Emerging Developments: Singlepoint and Innovus Pharmaceuticals - A Look Ahead into 2018Emerging Developments: Singlepoint and Innovus Pharmaceuticals - A Look Ahead into 2018
finance.yahoo.com - February 23 at 10:11 AM
Innovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® AssetsInnovus Pharma Announces the Complete Repayment in Cash of its Financial Obligations from its Acquisition of its Beyond Human® Assets
finance.yahoo.com - February 22 at 9:58 AM
SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with Target Price of $0.70SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with Target Price of $0.70
finance.yahoo.com - February 13 at 4:57 PM
Innovus Pharma Announces the Publication of a Successful Clinical Trial in Overactive Bladder and Urine Incontinence Patients for its UriVarx® ProductInnovus Pharma Announces the Publication of a Successful Clinical Trial in Overactive Bladder and Urine Incontinence Patients for its UriVarx® Product
finance.yahoo.com - February 7 at 8:40 AM
Innovus Pharma Expands Its Sales Channels Through an Alliance with Wellmed, LP to Access Their Extensive Direct Mailing Network of 500,000 Current CustomersInnovus Pharma Expands Its Sales Channels Through an Alliance with Wellmed, LP to Access Their Extensive Direct Mailing Network of 500,000 Current Customers
finance.yahoo.com - February 2 at 8:37 AM
Two Innovus Pharma Products Officially Listed in OTC Section of the RED BOOK™Two Innovus Pharma Products Officially Listed in OTC Section of the RED BOOK™
finance.yahoo.com - December 14 at 11:07 AM
Contrasting Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)Contrasting Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 13 at 3:53 PM
Head to Head Survey: Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)Head to Head Survey: Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)
www.americanbankingnews.com - December 11 at 1:38 PM
Comparing Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals (TNXP)Comparing Innovus Pharmaceuticals (INNV) & Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 10 at 9:08 PM
Reviewing Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)Reviewing Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)
www.americanbankingnews.com - December 9 at 7:18 PM
Contrasting Echo Therapeutics (ECTE) & Innovus Pharmaceuticals (INNV)Contrasting Echo Therapeutics (ECTE) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 9 at 11:54 AM
Tonix Pharmaceuticals (TNXP) vs. Innovus Pharmaceuticals (INNV) Head-To-Head ReviewTonix Pharmaceuticals (TNXP) vs. Innovus Pharmaceuticals (INNV) Head-To-Head Review
www.americanbankingnews.com - December 8 at 3:50 PM
Head to Head Contrast: Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)Head to Head Contrast: Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - December 6 at 1:28 AM
Comparing Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)Comparing Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 5 at 9:34 AM
Head to Head Comparison: Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV)Head to Head Comparison: Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 5 at 3:32 AM
Reviewing Tonix Pharmaceuticals (TNXP) and Innovus Pharmaceuticals (INNV)Reviewing Tonix Pharmaceuticals (TNXP) and Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - December 3 at 1:48 AM
Reviewing Echo Therapeutics (ECTE) & Innovus Pharmaceuticals (INNV)Reviewing Echo Therapeutics (ECTE) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 30 at 7:46 PM
Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV) Financial AnalysisEcho Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV) Financial Analysis
www.americanbankingnews.com - November 30 at 1:28 AM
Comparing Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)Comparing Innovus Pharmaceuticals (INNV) and Tonix Pharmaceuticals (TNXP)
www.americanbankingnews.com - November 28 at 11:40 AM
Critical Review: Innovus Pharmaceuticals (INNV) versus Tonix Pharmaceuticals Holding Corp. (TNXP)Critical Review: Innovus Pharmaceuticals (INNV) versus Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - November 24 at 1:20 PM
Innovus Pharmaceuticals, Inc. (INNV) Upgraded at Zacks Investment ResearchInnovus Pharmaceuticals, Inc. (INNV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 23 at 10:40 PM
Critical Analysis: Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV)Critical Analysis: Echo Therapeutics (ECTE) versus Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 22 at 3:42 PM
SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with a Price Target of $0.65SeeThruEquity Issues Update on Innovus Pharmaceuticals (INNV) with a Price Target of $0.65
finance.yahoo.com - November 17 at 7:23 AM
Comparing Tonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV)Comparing Tonix Pharmaceuticals Holding Corp. (TNXP) & Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 16 at 3:38 PM
Financial Comparison: Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)Financial Comparison: Innovus Pharmaceuticals (INNV) and Echo Therapeutics (ECTE)
www.americanbankingnews.com - November 16 at 1:08 PM
Critical Analysis: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)Critical Analysis: Tonix Pharmaceuticals Holding Corp. (TNXP) vs. Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 15 at 5:27 PM
Head to Head Contrast: Tonix Pharmaceuticals Holding Corp. (TNXP) versus Innovus Pharmaceuticals (INNV)Head to Head Contrast: Tonix Pharmaceuticals Holding Corp. (TNXP) versus Innovus Pharmaceuticals (INNV)
www.americanbankingnews.com - November 15 at 3:30 PM
Innovus Pharmaceuticals, Inc. (INNV) Posts  Earnings ResultsInnovus Pharmaceuticals, Inc. (INNV) Posts Earnings Results
www.americanbankingnews.com - November 15 at 12:54 PM

SEC Filings

Innovus Pharmaceuticals (OTCMKTS:INNV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Innovus Pharmaceuticals (OTCMKTS INNV) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.